Replies to post #33168 on Biotech Values

[DewDiligence]

> NBIX – They should likely be reporting on their meetings with FDA in that timeframe<

In that case, it’s reasonable to infer that the company does not expect positive developments from these meetings. If they did, they surely would not have scheduled the option re-pricing to occur after the news is released.